8-KMaterial Agreements

AMGEN INC 8-K Report, Agreement Terminated (Oct 5, 2009)

Filed October 5, 2009For Securities:AMGN

Summary

Amgen Inc. filed an 8-K report on October 5, 2009, to announce the termination of a material definitive agreement. Specifically, the Enbrel Supply Agreement, originally dated November 5, 1998, and subsequently amended, was terminated by all parties involved on September 30, 2009. The agreement involved Amgen's subsidiary, Immunex Corporation, along with Wyeth and Boehringer Ingelheim Pharma KG. This termination is a significant event for investors as Enbrel is a key product for Amgen. While the filing does not detail the reasons for termination or the specific impact on future supply or sales, it signals a change in the contractual arrangements surrounding the distribution or manufacturing of this important biologic therapy. Investors should closely monitor subsequent filings and company communications for further details on the implications of this termination on Amgen's operations and financial performance.

Key Highlights

  • 1Amgen announced the termination of the Enbrel Supply Agreement.
  • 2The termination was effective September 30, 2009.
  • 3The agreement involved Immunex Corporation (an Amgen subsidiary), Wyeth, and Boehringer Ingelheim Pharma KG.
  • 4The original agreement dated back to November 5, 1998, and had been amended.
  • 5This filing is a Form 8-K, indicating a material event requiring prompt disclosure.
  • 6The termination involves a key drug for Amgen, Enbrel.

Frequently Asked Questions

The Enbrel Supply Agreement was a contract originally dated November 5, 1998, involving Amgen's subsidiary Immunex Corporation, Wyeth, and Boehringer Ingelheim Pharma KG. The exact nature of the agreement is not detailed in this filing but likely pertained to the supply, manufacturing, or distribution of Enbrel.

Enbrel is a significant product for Amgen. The termination of a material supply agreement related to such a key drug can have implications for the company's revenue, supply chain, and future commercialization strategies. Investors need to understand how this change might affect Amgen's financial performance.

This 8-K filing does not specify the reasons behind the termination of the Enbrel Supply Agreement. It only reports that the agreement was terminated by all parties involved.

The immediate impact is not detailed in this filing. However, the termination signifies a change in the contractual relationship concerning Enbrel. Amgen will need to manage its supply, manufacturing, and potentially distribution of Enbrel under new or revised arrangements, the details of which are not provided here.